VistaGen Therapeutics Revenue and Competitors

Location

$54.8M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • VistaGen Therapeutics's estimated annual revenue is currently $892.7M per year.(i)
  • VistaGen Therapeutics's estimated revenue per employee is $20,289,091
  • VistaGen Therapeutics's total funding is $54.8M.
  • VistaGen Therapeutics's current valuation is $341.7M. (January 2022)

Employee Data

  • VistaGen Therapeutics has 44 Employees.(i)
  • VistaGen Therapeutics grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.4M2-67%N/AN/A
#2
$32M1593%N/AN/A
#3
$35M1213%$62.5MN/A
#4
$30.2M15018%N/AN/A
#5
$135.9M676-1%N/AN/A
#6
$14.9M972%$173MN/A
#7
$110.3M549N/AN/AN/A
#8
$62.7M312-3%N/AN/A
#9
$4.9M4932%N/AN/A
#10
$9.2M46-2%N/AN/A
Add Company

VistaGen Therapeutics (http://www.vistagen-inc.com), a private biotechnology company located in Burlingame, California, USA, is one of the global leaders in the in vitro applications of stem cell technologies for drug discovery and development. VistaGen's portfolio of proprietary stem cell technologies and information products are being introduced to the pharmaceutical industry to accelerate drug development in ways never before possible. VistaGen's internal drug discovery and development programs focusing on cancer, central nervous system (CNS) disorders, and cardiovascular disease will also benefit from the development of these screening systems.

keywords:N/A

$54.8M

Total Funding

44

Number of Employees

$892.7M

Revenue (est)

0%

Employee Growth %

$341.7M

Valuation

N/A

Accelerator

VistaGen Therapeutics News

2022-04-19 - VistaGen Therapeutics : to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses - Form 8-K

With an experienced leadership team and a steady flow of near- and long-term potential milestones, VistaGen is passionate about transforming...

2022-04-17 - VistaGen to Present Preclinical Data on Lead Candidate ...

VistaGen Therapeutics, Inc. ... VistaGen is currently evaluating PH94B in multiple Phase 3 trials for the acute treatment of anxiety in adults...

2022-03-30 - How Does Vistagen Therapeutics Inc (VTGN) Stock Rank on Wall Street Monday?

Wall Street is positive on Vistagen Therapeutics Inc (VTGN). On average, analysts give the stock a Strong Buy rating.

2020-12-10 - VistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 Patent for Treatment of Depression

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders ...

2008-12-22 - VistaGen gobbles up $1M for stem-cell research

South San Francisco-based biotech firm VistaGen Therapeutics raised $1 million in grant funding from the California Institute for Regenerative Medicine (CIRM) to distribute to researchers and other companies working on stem-cell projects linked to diabetes and neurological disorders, reports Ven ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.8M4433%N/A
#2
$7M4536%N/A
#3
$9.7M4522%N/A
#4
$33.6M45-10%$98M
#5
$7.1M462%N/A